Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma

Clinical Trial ID NCT01881789

PubWeight™ 3.99‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01881789

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals (Basel) 2014 0.91
2 Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant 2016 0.82
3 Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? Onco Targets Ther 2016 0.76
4 Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. J Mol Med (Berl) 2015 0.75
5 Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol 2014 0.75
Next 100